Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22508602 | 0.81 | ADORA2A (0.57) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL20758215 | 0.81 | ADORA1 (0.40) | ADORA2AADORA1ADORA3ADORA2BCDK1 | |
| SCHEMBL20755889 | 0.78 | ADORA2A (0.35) | ADORA2AADORA1ADORA3ADORA2BCDK1 | |
| SCHEMBL5732055 | 0.70 | TLR7 (0.43) | ADORA2AADORA1 | |
| SCHEMBL20897177 | 0.66 | ADORA2A (0.35) | ADORA2AADORA1 | |
| SCHEMBL20755691 | 0.65 | MEN1 (0.39) | ADORA2AADORA1CDK1 | |
| SCHEMBL18165669 | 0.64 | CDK1 (0.60) | ADORA2AADORA1ADORA2BCDK1CCNB1 | |
| SCHEMBL27405153 | 0.63 | ADORA1 (0.41) | ADORA2AADORA1ADORA3ADORA2BCDK1 | |
| SCHEMBL5732033 | 0.63 | KDM4E (0.39) | ADORA2AADORA1 | |
| SCHEMBL11284152 | 0.63 | ADORA2A (0.36) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3668872-B1 | 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS IMMUNOSTIMULANT TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210113706-A1 | MODIFIED SELF-IMMOLATING MOIETIES FOR USE IN PRODRUGS AND CONJUGATES AND METHODS OF USING AND MAKING | BRISTOL-MYERS SQUIBB COMPANY | 2021-04-22 | — | — | US | disclosed |
| US-20210053979-A1 | MACROCYCLIC TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| US-10494370-B2 | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-03 | — | — | US | disclosed |
| WO-2019035968-A1 | 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AS IMMUNOSTIMULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055245-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | PAICS, UGT1A1, CYP7A1 | ADORA2A 2127/4885ADORA1 1571/4885ADORA3 2401/4885 |
| US-20210053979-A1 | MACROCYCLIC TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | ADORA2A 469/4885ADORA1 806/4885ADORA3 891/4885 |
| US-20190055245-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR4 | ADORA2A 200/4885ADORA1 126/4885ADORA3 282/4885 |
| US-10494370-B2 | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR4 | ADORA2A 200/4885ADORA1 126/4885ADORA3 282/4885 |
| US-20210113706-A1 | MODIFIED SELF-IMMOLATING MOIETIES FOR USE IN PRODRUGS AND CONJUGATES AND METHODS OF USING AND MAKING | PAICS, UGT1A1, CYP7A1 | ADORA2A 2127/4885ADORA1 1571/4885ADORA3 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.